
ApoB testing could redefine cholesterol screening, surpassing LDL in predicting heart risk
A new JAMA study finds measuring apolipoprotein B (apoB) in cholesterol screening may more accurately identify who needs treatment to prevent heart attacks and strokes than LDL or non-HDL cholesterol. The findings align with updated guidelines that emphasize additional tests, like Lp(a), for assessing risk, and suggest apoB can reveal cardiovascular risk even when LDL appears normal.













